These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
499 related items for PubMed ID: 16799979
1. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979 [Abstract] [Full Text] [Related]
2. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452 [Abstract] [Full Text] [Related]
3. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Am J Gastroenterol; 2004 Sep; 99(9):1708-17. PubMed ID: 15330907 [Abstract] [Full Text] [Related]
4. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618 [Abstract] [Full Text] [Related]
5. Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? Canbakan B, Senturk H, Canbakan M, Toptas T, Tabak O, Balci H, Olgac V, Ozbay G. Biomark Med; 2010 Apr; 4(2):205-14. PubMed ID: 20406065 [Abstract] [Full Text] [Related]
6. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ. J Clin Gastroenterol; 2010 Apr; 44(4):e87-95. PubMed ID: 19881359 [Abstract] [Full Text] [Related]
7. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877 [Abstract] [Full Text] [Related]
8. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963 [Abstract] [Full Text] [Related]
9. [Clinical and histological features of non-alcoholic fatty liver disease]. Shi JP, Xun YH, Hu CB, Zhang L, Liu H, Lou GQ, Fan JG. Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638 [Abstract] [Full Text] [Related]
10. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Yerci O, Oral AY, Gul CB, Gurel S, Nak SG, Gulten M. Med Sci Monit; 2009 Apr; 15(4):CR189-93. PubMed ID: 19333204 [Abstract] [Full Text] [Related]
11. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Ito S, Yukawa T, Uetake S, Yamauchi M. Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172 [Abstract] [Full Text] [Related]
12. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Tahan V, Canbakan B, Balci H, Dane F, Akin H, Can G, Hatemi I, Olgac V, Sonsuz A, Ozbay G, Yurdakul I, Senturk H. Hepatogastroenterology; 2008 Jan; 55(85):1433-8. PubMed ID: 18795706 [Abstract] [Full Text] [Related]
13. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754 [Abstract] [Full Text] [Related]
14. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients. Valva P, De Matteo E, Galoppo M, Pedreira A, Giacove G, Lezama C, Marco I, Galoppo MC, Preciado MV. Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620 [Abstract] [Full Text] [Related]
15. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244 [Abstract] [Full Text] [Related]
18. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Wieckowska A, McCullough AJ, Feldstein AE. Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414 [Abstract] [Full Text] [Related]
19. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Hepatology; 2005 Sep; 42(3):650-6. PubMed ID: 16037946 [Abstract] [Full Text] [Related]